Disease · HP_0001410
Decreased liver function
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Decreased liver function. Diseases, record HP_0001410. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001410
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Decreased liver function
- Open Targets ID
- HP_0001410
- Other names
- Liver dysfunction
- Highest stage of its drugs
- Approval, for 1 of its 4 drugs, from PMDA
Source Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE | CHEMBL1486 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| SEBELIPASE ALFA | CHEMBL3039537 | Enzyme | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ELTROMBOPAG | CHEMBL461101 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Unknown | https://conductscience.org/library/genes/3643 | Drugs and targets |
| MPL | Thrombopoietin receptor | 1 | Thrombopoietin receptor agonist | Unknown | https://conductscience.org/library/genes/4352 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01307098 | Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency | Phase 1/2 | 9 | 2018-12-11 | Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency | SEBELIPASE ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT07093606 | Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura | Not applicable | 100 | ITP - Immune Thrombocytopenia | ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov | |
| NCT06126419 | Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration | Not applicable | 70 | Liver Dysfunction, Liver Metastasis Colon Cancer, Liver Regeneration | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 23348766 | RESULT | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001410
GET https://conductscience.org/api/diseases/v1/HP_0001410/drugs